Gossamer Bio (GOSS) CEO Hasnain Faheem Receives Award

What Happened

• Hasnain Faheem, President & CEO and a director of Gossamer Bio (GOSS), reported equity acquisitions on 2026-08-24. He acquired 166 shares at $1,000.00 each (total $166,000) and was granted 5,800,051 pre‑funded warrants at $0.00. Both entries are reported as derivative awards/acquisitions (transaction code A).

Key Details

• Transaction date: 2026-08-24; Form 4 filed 2026-08-26.
• Items acquired:
  • 166 Series A‑1 non‑voting convertible preferred shares at $1,000.00 each = $166,000.
  • 5,800,051 Pre‑Funded Warrants at $0.00 (no cash paid for the warrants).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Notable footnotes from the filing:
  • F1: Each Series A‑1 preferred share converts, upon required stockholder approval, into common shares equal to $1,000 ÷ $0.14 (≈ 7,142.86 common shares per preferred), subject to beneficial ownership limitations.
  • F2: The Pre‑Funded Warrants have no expiration and are exercisable immediately. Before company stockholder approval they may be exercised only for Series A‑1 preferred; after stockholder approval they are exercisable for common stock.
  • F3: (Relating to an option grant referenced in the filing) 50% of the option vests upon FDA approval of seralutinib, with the remainder vesting monthly over up to 24 months, or starting two years after grant if FDA approval has not occurred by then.
• Timeliness: Filing date is two days after the reported transaction date (no late‑filing indication in the excerpt).

Context

• These are derivative/equity awards rather than open‑market purchases or sales. The 166 preferred shares were purchased for cash; the large block of 5.8M instruments are pre‑funded warrants exercisable into preferred (now) and into common after stockholder approval — they carry potential future common share issuance subject to conversion mechanics and ownership limits.
• For retail investors: awards and pre‑funded warrants can materially increase potential future share count depending on conversion/exercise and approval steps. This filing documents management receiving structured equity as part of a private placement arrangement; it does not by itself indicate an immediate market buy or sale of common shares.